Oral Immunotherapy in Turkey

What Is Oral Immunotherapy for Food Allergy?

Oral immunotherapy, usually shortened to OIT, is a specialist treatment approach for an established food allergy. It involves taking controlled amounts of the relevant food according to an individual clinical programme. A central aim is to increase the amount tolerated while treatment continues. This is different from independently trying small amounts at home, and different from simply adding a food to an ordinary diet.

When you enquire about OIT in Turkey, ask for an assessment rather than assuming that programme entry is already agreed. The doctor needs to understand the diagnosis, the food involved, previous reactions and your wider circumstances. This page explains the decisions and commitments to discuss. It does not provide a starting dose, an escalation schedule or instructions for restarting treatment after a break.

Desensitisation, Remission and the Meaning of Success

Desensitisation means that a person can tolerate more allergen under the treatment conditions, usually with continued exposure. Remission or sustained unresponsiveness refers to retaining benefit after treatment is stopped for a defined period; these are not interchangeable outcomes. In the POISED peanut trial, stopping treatment or reducing exposure was associated with loss of protection in many participants. That finding supports careful discussion of ongoing treatment rather than a promise of permanent tolerance.

Ask what your proposed programme is trying to achieve and how that goal would be assessed. A supervised challenge result does not automatically mean unrestricted eating in every situation. Before deciding, explain what would make treatment worthwhile to you: less anxiety around accidental exposure, a particular dietary goal or clearer information about options. The clinician should explain which goals are realistic and which cannot be promised.

Which Food Allergies Can Be Considered for OIT?

The strength of evidence differs by food and age. EAACI recommends OIT for appropriate children and adolescents with peanut allergy and suggests it for selected milk and egg allergy cases, generally after four years for milk and egg. This does not establish an identical recommendation for all other foods or guarantee that every centre provides the same programmes.

Tell our team the exact food when requesting an appointment. If more than one food is involved, list them separately and explain which have caused reactions. Ask which programmes are available and whether the enquiry concerns an established service, a possible individual assessment or something not currently offered. Milk, egg, peanut and tree nuts should not be treated as interchangeable categories just because they are all foods. A recommendation for one allergen does not authorise treatment for another.

Peanut OIT: Interpreting Evidence Without a Personal Guarantee

Peanut is one of the best studied foods in OIT research. Evidence includes studies of older children and research in younger age groups. In the IMPACT trial, treatment produced desensitisation in many young children and protocol-defined remission in a smaller subset. These outcomes were assessed using the trial’s own eligibility rules, treatment period and challenge definitions.

For a consultation, the useful question is not simply whether peanut OIT “works”. Ask what the evidence means for the patient’s age, history, goals and proposed programme. Avoid interpreting a result from a trial as your own predicted outcome. The food preparation, treatment period and follow-up used in a study may differ from another programme. A responsible discussion should make those differences visible before decisions are made.

Milk, Egg and Other Food-Specific Programmes

Clinical research has evaluated egg OIT in children, with desensitisation and outcomes after withdrawal assessed separately. This illustrates why programme progress and benefit after stopping treatment need different definitions. Evidence from a particular egg study should not be converted into instructions to introduce egg at home, or assumed to apply to every milk or tree nut programme.

Ask the treating clinician about the actual form of food used, the intended objective and the reasons for choosing the proposed approach. Different preparations cannot be substituted simply because their names sound similar. If you are enquiring about milk, egg, hazelnut, cashew or another food, confirm availability specifically. Detailed food-specific pages can explain each pathway, but the final instructions must come from the team responsible for the individual programme.

Confirming the Diagnosis Before Treatment

OIT assessment starts with a clear clinical question. An allergy-focused history, relevant IgE or skin testing and selected additional investigations can contribute to diagnosis. Sensitisation on a test does not, on its own, establish clinical allergy. Component testing and BAT may help in defined circumstances where appropriate testing is available, but every patient does not need every test.

Bring complete reports rather than only a list of positive allergens. Include when reactions occurred and whether the food has been eaten since. Tell your doctor about restrictions based on uncertain screening results as well as restrictions following convincing reactions. If the diagnosis is unresolved, the first appointment may be about clarification rather than starting treatment. Confirm whether additional investigations would change the decision and how they would be scheduled.

How Is a Food Challenge Different from OIT?

A supervised oral food challenge is a diagnostic or assessment procedure in which a food is given under medical observation. OIT is an ongoing treatment programme. A challenge may be discussed to clarify diagnosis or assess a treatment outcome, but it is not automatically necessary at every stage or included in every consultation.

Ask why a challenge is being proposed and what decision will follow its result. Confirm preparation, observation time and any separate fee. Do not interpret a planned challenge as permission to test the food at home before travelling. If a procedure is postponed because the clinical circumstances have changed, ask the team how the schedule should be revised. A travel booking should not determine whether a supervised procedure is medically appropriate.

Who May Be Suitable, and When Might Treatment Be Deferred?

Suitability depends on medical and practical factors. CSACI guidance identifies uncontrolled asthma as a contraindication to starting OIT; other conditions, including a history of eosinophilic oesophagitis, require particular consideration. Reliable adherence, the ability to recognise and manage reactions, and the patient’s willingness are important parts of assessment. A previous severe reaction needs discussion but does not allow suitability to be decided from a website alone.

Explain health problems, swallowing symptoms, feeding difficulties and any concerns about treatment responsibilities before a programme is agreed. Tell the team if follow-up travel, language barriers or access to urgent care could create difficulties. The decision may be to proceed, investigate further, address another condition first or continue a different management plan. Deferring OIT can be an appropriate clinical decision rather than a failure of the consultation.

OIT Assessment for Children and Adolescents

For a child, the treatment conversation should include the child’s experience as well as the parent’s goals. Consider food acceptance, school commitments, the people responsible for treatment and the possibility of changes in routine. A plan understood by one parent may be difficult when another caregiver supervises meals or when a child stays elsewhere. Ask how the programme would handle these transitions before the family commits.

Adolescents should be encouraged to ask questions and explain what feels manageable. Discuss education, sports, social events and increasing independence without assuming that a young person will follow a plan simply because adults agreed to it. Ask the team how progress and concerns will be reviewed. The appointment should clarify the responsibilities of the patient, caregivers and clinic, including what information is needed when symptoms or circumstances change.

Can Adults Enquire About Oral Immunotherapy?

Adults can enquire about an OIT assessment, but adult evidence is less extensive than the paediatric literature for many foods. The 2025 GUPI study reported peanut OIT outcomes in a small adult cohort and called for further research. It provides evidence that adult treatment deserves consideration, not proof that all adults or all foods have the same outcomes.

Tell Istanbul Allergy the patient’s age, food and reason for the enquiry so the appointment scope can be confirmed. Ask how the proposed option fits employment, repeated travel and access to follow-up where you live. Do not assume that a programme described for a young child applies unchanged to an adult. An assessment may help clarify alternatives and ongoing management even if a particular programme is not offered or recommended.

The First Consultation and Baseline Planning

Expect the initial discussion to bring together previous reactions, current restrictions, existing investigations and treatment goals. Have a medication list and relevant clinical reports ready. Ask whether any further assessment is needed before programme entry, how the goal will be documented and what arrangements would apply if the plan changes. The first visit should establish a shared understanding rather than rush towards a starting date.

This is also the time to discuss the practical terms of care. Ask which visits are supervised, what preparation is expected, how you will receive written instructions and how routine questions are handled. If you are travelling, explain your available dates honestly. Do not assume that a shorter trip can be accommodated by accelerating treatment; scheduling needs to follow clinical requirements, not the other way round.

Understanding the Main Phases of an OIT Programme

Programmes commonly distinguish an initial supervised stage, a build-up period and maintenance. The amounts, number of visits and time spent in each stage are not universal. A published protocol should not be copied into home practice or interpreted as the clinic’s proposed schedule. Ask for an explanation of the stages that would apply to you, including what has to happen before moving between them.

Use the overview below to understand the conversation rather than calculate doses. It separates decisions made before treatment, supervised progression and the responsibilities of longer-term care. If the programme is interrupted or symptoms arise, the clinical team may need to reassess the next step. The written plan should explain how to obtain advice; it should not rely on your interpretation of a general information page.

Supervised Visits and the Build-up Period

Before a supervised visit, ask whether there are preparation instructions and whether a change in health needs to be reported. Confirm what to bring, how long to allow and the arrangements if the patient cannot attend. The team should explain what happens during observation and when it is appropriate to leave. Do not plan a flight or another inflexible commitment around an assumed observation period without checking.

During build-up, progression should follow the treating team’s instructions. Taking more because previous amounts were tolerated, changing preparations or adding an extra exposure is not an appropriate way to speed the programme. Ask how decisions about increasing, delaying or reviewing treatment are communicated. The relevant question is whether the next step is suitable today, not whether the calendar says you should already be at a later stage.

Home Treatment Responsibilities and Written Instructions

If a programme includes home administration, obtain clear written instructions specific to that programme. Confirm the preparation, measuring method, timing and observation requirements with the team. Identify who will supervise and who needs training. If food preparation is part of the plan, ask how products should be stored and whether any substitutions are allowed. A household utensil or familiar serving description is not automatically an accurate treatment measure.

Keep the plan accessible and check that every responsible caregiver understands it. Ask what information to record and how routine questions should be raised. Home treatment is not independent treatment: the supervising service remains responsible for giving the programme instructions. This page intentionally provides no doses or dilution recipes. For an error or uncertainty, contact the team for the appropriate next step rather than compensating with a guessed amount.

Maintenance and Longer-Term Commitment

Reaching maintenance does not necessarily mean treatment is complete. Continued exposure may be required to retain desensitisation, and the long-term plan needs regular review. Ask what maintenance means for your programme, what endpoint is being assessed and whether future supervised assessments are planned. Avoid confusing a clinic milestone with a guarantee of unrestricted eating or permanent tolerance.

Before starting, consider whether maintenance is feasible after returning home, changing schools, moving house or travelling. Clarify the arrangements for obtaining the prescribed preparation and attending review appointments. If you cannot meet the proposed requirements, discuss that openly. A sustainable alternative may be more appropriate than a demanding plan that cannot be followed reliably. Do not change or stop maintenance solely because the patient currently feels well.

Expected Benefits and the Limits of Success Rates

A higher tolerated amount during a supervised challenge is a common research outcome. PACE found that peanut OIT increased the likelihood of passing such a challenge while also increasing treatment-related allergic reactions compared with avoidance or placebo. These findings show why benefit and harm need to be discussed together rather than presenting one success percentage as the whole story.

Ask which outcome a quoted rate describes, which patients were included and how long they were followed. Was the percentage calculated among everyone who started or only those who completed the programme? Does it refer to treatment exposure, a challenge result or benefit after stopping? No clinic-specific success statistic is provided here because an individual prediction requires relevant evidence and a clear definition. Request an explanation suited to your own food, age and clinical circumstances.

Allergic Reactions and Emergency Preparedness During OIT

OIT can cause reactions, including anaphylaxis. The possibility of increasing a threshold does not remove the need to recognise symptoms and respond appropriately. Treatment-related reactions can occur during supervised progression and ongoing treatment; prior tolerance is not a reason to dismiss a new reaction.

Before starting, make sure you understand the prescribed emergency action plan and the use of any adrenaline auto-injector. Adrenaline is first-line treatment for anaphylaxis; antihistamines do not replace it for a severe reaction. If a serious reaction occurs, follow the emergency plan and seek immediate local emergency help rather than waiting for a routine clinic reply.

Ask how a reaction affects subsequent programme decisions once urgent care has been addressed. The team may need the symptom history, treatment given and the circumstances of the exposure. Do not restart or increase treatment on your own after a reaction because the episode has resolved. Routine communication and emergency care serve different purposes and both need to be arranged in advance.

Persistent Stomach Symptoms and Eosinophilic Oesophagitis

Persistent abdominal symptoms, vomiting, feeding difficulty or swallowing problems need clinical review during an OIT programme. Eosinophilic oesophagitis is an inflammatory condition of the oesophagus that can involve swallowing difficulty, discomfort and food-related symptoms. It cannot be diagnosed from one symptom or a website description; further specialist evaluation may be needed.

Do not assume repeated symptoms are an unavoidable price of progress or try to work around them by changing the food preparation yourself. Report the problem and ask how the programme should be managed while it is assessed. Keep a clear account of when symptoms occur and what was taken. The aim of follow-up is not simply to reach a target amount; it is to review tolerability and whether the plan remains appropriate for the patient.

Illness, Exercise, Missed Treatment and Changes in Routine

OIT instructions often address circumstances that can affect the tolerability of a dose, such as illness, exercise and heat exposure. The requirements are programme-specific; do not assume that an online timetable or another family’s instructions apply to you. Ask how those circumstances should be managed and what changes need reporting.

Missed treatment requires the instructions supplied by your own service. Do not double an amount, resume a previous level after a break or use an internet rule to decide whether to continue. Ask for written missed-dose and restarting arrangements before they are needed. If holidays, overnight travel or work shifts make the routine difficult, raise that during planning so the team can explain the limitations rather than leaving you to improvise.

Other Food Allergies, Everyday Eating and Dietary Goals

Treatment for one food is not permission to relax restrictions for a different food. Clarify what remains excluded, what ordinary eating is allowed and which exposures belong only within the prescribed programme. When several foods are involved, ask whether they are being considered separately and how each diagnosis has been established. A single positive screening list does not automatically justify treating every listed item.

Keep the nutritional and social goals visible during follow-up. Discuss meals, food acceptance and any anxiety or practical burden created by treatment. If a dietary review is recommended, confirm how it will be arranged. Parents and adults should be able to say when a programme is difficult without feeling that reporting problems means they have failed. That information helps the clinician reassess what a workable plan should look like.

OIT and Omalizumab: Separate Questions to Discuss

Omalizumab is a biological medicine that may be discussed in food-allergy care. Its US food-allergy approval concerns reducing reactions after accidental exposure; it is not emergency treatment and does not allow free consumption of allergens. Any local indication, availability and funding in Turkey must be confirmed independently.

If you are asking about treatment combined with OIT, request a separate explanation of the proposed purpose, monitoring and ongoing arrangements. A webpage mentioning combination treatment does not confirm that a particular patient should receive it. Ask what would happen if the medicine were not available after returning home and how the clinical team would coordinate care. Do not assume that a medicine removes OIT-related precautions or makes a programme suitable without assessment.

Travelling to Turkey for an OIT Assessment

Begin by telling our team the patient’s age, food allergy diagnosis, relevant food and purpose of the enquiry. Specify whether you want a first discussion, assessment for programme entry or advice about an existing programme elsewhere. These are different requests and may require different records and appointment arrangements. Confirm the service scope before booking travel.

Ask for provisional scheduling while recognising what cannot be established until assessment. Separate the initial consultation from investigations, supervised stages and later reviews. An OIT programme should not be marketed as a single short holiday that removes a food allergy. Review the Plan Your Visit checklist and discuss follow-up requirements before committing to a treatment-related stay.

Continuing Care After Returning Home

Before starting a programme abroad, identify who will supervise the longer-term plan and how necessary clinical reviews will take place. Ask whether a local clinician needs to be involved and what access to urgent care is required. These arrangements should be agreed early, particularly if the proposed treatment continues after you leave Istanbul.

An online review can support selected discussions but cannot carry out every examination or supervised step. Confirm how records will be shared, how routine questions are handled and whether repeat visits are expected. If the proposed arrangement cannot be maintained in your home country, tell the clinician before treatment begins. Continuity is a central part of the decision, not an administrative detail to resolve at the airport.

Travel Planning While Managing Food Allergy

Carry your existing prescribed emergency medicines and action plan when travelling, and discuss preparation with your usual clinician. Make sure relevant travel companions know about the allergy and the response plan. Clear written information can help explain restrictions when language differs, while meals and ingredient questions still need individual attention.

For OIT, ask your treating service how travel interacts with the actual programme before changing dates or taking treatment away from home. Do not assume a preparation can be substituted locally. Confirm storage, transport and missed-appointment instructions with the service, and arrange suitable meals independently of treatment exposures. A clinic appointment does not by itself include accommodation, transfers or a guaranteed allergen-free food supply.

How Long Does OIT Take, and What Affects the Cost?

There is no single duration or price for every OIT programme. Assessment, supervised appointments, treatment preparation, investigations and follow-up can each contribute to the total commitment. Ask what the quoted amount includes and which future services are separate. Confirm how changes in schedule, postponement or discontinuation would affect the practical and financial arrangements.

For a patient travelling from abroad, include repeated travel and time away from school or work in the decision. Ask what must be paid before assessment, what remains provisional and when a more complete plan can be discussed. A low initial consultation fee does not describe the entire cost of care. Contact Istanbul Allergy for current service information; this page does not promise a package price, fixed completion date or guaranteed programme acceptance.

Questions to Ask Before Agreeing to OIT

A useful decision should answer more than “Can I start?”. Ask what diagnosis supports treatment, why the proposed option fits the patient, what alternatives exist and which goals are realistic. Ask how the team evaluates progress and what would lead it to recommend a pause or a different plan. If any answer is unclear, request a practical explanation before agreeing.

You should also understand the expected supervision, written home instructions, review arrangements, full costs and continuity after returning home. Ask what the service provides for routine questions and distinguish it from local emergency care. Include the patient’s own priorities in the conversation. Choosing continued standard management, delaying a decision or seeking clarification are legitimate options; an enquiry should not create pressure to commit to a programme you do not yet understand.

OIT QUESTIONS

Frequently Asked Questions

Scientific Sources & Further Reading

Research protocols and overseas authorisations do not establish a local programme or personal eligibility. The overview below draws on guidelines and studies; individual instructions come from the treating clinical team.

1. AAAAI: The current state of oral immunotherapy. ↗
2. EAACI: Guidelines on the management of IgE-mediated food allergy. ↗
3. CSACI: Patient-oriented clinical practice guidelines for oral immunotherapy (2020). ↗
4. Chu et al.: PACE systematic review of peanut OIT efficacy and safety (2019). ↗
5. Chinthrajah et al.: POISED study of sustained outcomes following peanut OIT (2019). ↗
6. Hunter et al.: Oral immunotherapy in peanut-allergic adults — GUPI study (2025). ↗
7. Jones et al.: IMPACT randomised peanut OIT trial in young children (2022). ↗
8. Burks et al.: Oral immunotherapy for egg allergy in children (2012). ↗
9. AAAAI: Eosinophilic oesophagitis. ↗
10. AAAAI: Oral food challenges — patient information. ↗
11. EAACI: Guidelines on diagnosis of IgE-mediated food allergy (2023). ↗
12. FDA: Omalizumab for reducing reactions after accidental food exposure (2024). ↗
13. AAAAI: Anaphylaxis — treatment and emergency planning. ↗
14. FARE: Travelling with food allergies. ↗